The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prevalence of low-penetrance KRAS (codons 12/13 and 61) and BRAF mutations in metastatic colorectal carcinoma.
Federico Rojo
No relevant relationships to disclose
Trinidad Caldes
No relevant relationships to disclose
Sandra Zazo
No relevant relationships to disclose
Miguel de la Hoya
No relevant relationships to disclose
Cristina Carames
No relevant relationships to disclose
Atocha Romero
No relevant relationships to disclose
Gloria Serrano
No relevant relationships to disclose
Inmaculada Bando
No relevant relationships to disclose
Ana Leon
No relevant relationships to disclose
Javier Sastre
No relevant relationships to disclose
Jose Ignacio Martin-Valades
No relevant relationships to disclose
Lourdes Cillero
No relevant relationships to disclose
Angel Campos
No relevant relationships to disclose
Belen Gavina
No relevant relationships to disclose
Alberto Lendinez
No relevant relationships to disclose
Cristina Bausela
No relevant relationships to disclose
Dolores Ferrandez
Employment or Leadership Position - Roche/Genentech
Teresa Ramos
Employment or Leadership Position - Roche Diagnostics
Jesus Garcia-Foncillas
Consultant or Advisory Role - Roche
Research Funding - Roche
Eduardo Diaz-Rubio
Consultant or Advisory Role - Roche
Research Funding - Roche